B of A Securities Downgrades Achilles Therapeutics to Underperform, Lowers Price Target to $0.5
B of A Securities Downgrades Achilles Therapeutics to Underperform, Lowers Price Target to $0.5
Bof A Securities將Achilles Therapeutics的評級下調至表現不佳，將目標股價下調至0.5美元
B of A Securities analyst Tazeen Ahmad downgrades Achilles Therapeutics (NASDAQ:ACHL) from Buy to Underperform and lowers the price target from $7 to $0.5.
Bof A Securities分析師塔澤恩·艾哈邁德將Achilles Therapeutics（納斯達克股票代碼：ACHL）的評級從買入下調至表現不佳，並將目標股價從7美元下調至0.5美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。